FDA grants orphan status to Dusa drug
Esophageal dysplasia occurs in some patients with Barrett’s esophagus, a leading cause of esophageal cancer. The incidence of esophageal cancer is one of the most rapidly growing in
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.